Ambrx Biopharma Inc.
Ambrx Biopharma Inc. (AMAM) Revenue
Annual & quarterly revenue history · segment & region breakdown
AMAM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAmbrx Biopharma Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 0.71% year-over-year from $0.01B in FY2022.
Revenue trend
2022 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.01B | -$0.00B | -0.71% |
| 2021-12-31 | $0.01B | -$0.01B | -45.47% |
| 2020-12-31 | $0.01B | +$0.00B | +32.59% |
| 2019-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare AMAM revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ambrx Biopharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ambrx Biopharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ambrx Biopharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AMAM revenue · 4 questionsAMAM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 0.71% year-over-year from $0.01B in FY2022.
▸ Source: FMP · Ambrx Biopharma Inc. SEC filings · GAAP · Ambrx Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026